全文获取类型
收费全文 | 4741篇 |
免费 | 317篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 141篇 |
妇产科学 | 78篇 |
基础医学 | 631篇 |
口腔科学 | 440篇 |
临床医学 | 446篇 |
内科学 | 1020篇 |
皮肤病学 | 158篇 |
神经病学 | 296篇 |
特种医学 | 374篇 |
外科学 | 450篇 |
综合类 | 28篇 |
预防医学 | 412篇 |
眼科学 | 41篇 |
药学 | 339篇 |
中国医学 | 40篇 |
肿瘤学 | 144篇 |
出版年
2023年 | 46篇 |
2022年 | 88篇 |
2021年 | 163篇 |
2020年 | 109篇 |
2019年 | 143篇 |
2018年 | 188篇 |
2017年 | 103篇 |
2016年 | 147篇 |
2015年 | 142篇 |
2014年 | 218篇 |
2013年 | 207篇 |
2012年 | 357篇 |
2011年 | 334篇 |
2010年 | 198篇 |
2009年 | 189篇 |
2008年 | 241篇 |
2007年 | 243篇 |
2006年 | 181篇 |
2005年 | 163篇 |
2004年 | 144篇 |
2003年 | 162篇 |
2002年 | 138篇 |
2001年 | 77篇 |
2000年 | 90篇 |
1999年 | 68篇 |
1998年 | 60篇 |
1997年 | 71篇 |
1996年 | 80篇 |
1995年 | 56篇 |
1994年 | 51篇 |
1993年 | 61篇 |
1992年 | 43篇 |
1991年 | 29篇 |
1990年 | 31篇 |
1989年 | 44篇 |
1988年 | 49篇 |
1987年 | 47篇 |
1986年 | 48篇 |
1985年 | 39篇 |
1984年 | 32篇 |
1983年 | 18篇 |
1982年 | 25篇 |
1981年 | 21篇 |
1980年 | 10篇 |
1978年 | 10篇 |
1977年 | 19篇 |
1976年 | 12篇 |
1975年 | 18篇 |
1971年 | 7篇 |
1969年 | 7篇 |
排序方式: 共有5072条查询结果,搜索用时 31 毫秒
91.
We have explored the polymorphism of the glycophorin system in the human erythrocyte membrane using the immunoblotting techniques and examining 52 individuals selected without prior bias as to their serologic state and ten documented serologic variants of M, N, S, s blood group system. Polyclonal antisera to alpha glycophorin and to alpha glycophorin CNBr carboxyl terminal fragment C (residues 82-131) and M and N specific monoclonal antibodies (MoAbs) were used. The first two reagents detect specific regions of the alpha glycophorin molecule and all electrophoretically resolved species of glycophorins immunologically related to alpha and delta glycophorins (delta glycophorin, [alpha-delta] hybrids and other glycophorins with an alteration in the carboxyl terminal segment); the M and N MoAbs identified the glycophorin species containing or lacking the M or N determinant in the amino terminal octapeptide structures. We find that immunoblotting confirmed in all cases the serologically determined phenotype; we also find that polymorphic forms of the glycophorin system are relatively infrequent; immunoblotting, independent from serologic testing, was capable of detecting five mutants, two most likely S-s-U-phenotypes; a new glycophorin species was detected in normal red cells with both antiglycophorin and antipeptide C sera, which is not evident with MoAbs; immunoblots of known glycophorin variants (En(a-), U-, Mg, Mi I, II, III, V, and Sta) confirmed but also extended our knowledge of the abnormal glycophorins involved; and the He+ and Wrb(-) cells showed normal patterns. 相似文献
92.
Cytogenetic and histologic correlations in malignant lymphoma 总被引:9,自引:0,他引:9
Koduru PR; Filippa DA; Richardson ME; Jhanwar SC; Chaganti SR; Koziner B; Clarkson BD; Lieberman PH; Chaganti RS 《Blood》1987,69(1):97-102
Although a number of studies have indicated correlations between histologic subtypes of tumors and certain nonrandom chromosome changes, cytogenetic studies of lymphoma are in an early stage compared to those of leukemia. No comprehensive analysis of available data has so far been attempted in the literature either. Here we present an analysis of chromosome changes and their correlation with subtypes of lymphoma studied by conventional histology and cell surface markers, as observed in two sets of data: a group of 65 karyotypically abnormal tumors sequentially ascertained and studied by us during the period January 1, 1984 to April 30, 1985, and a larger data set derived by combining our data with those from two published series from the University of Minnesota that are comparable to our data. These combined data, which comprise the largest data set on the cytogenetics of lymphomas assembled so far, enabled a comprehensive analysis of correlation between chromosome change and tumor histology and the patterns of chromosome instability in these tumors. We found several significant associations, some previously described and others now recognized, between nonrandom chromosome gains, breaks, translocations, and deletions and histologic subtypes of tumors that characterize lymphomas. The data indicate that finding of chromosome breaks at certain sites (eg, 8q24, 14q32, 18q21) is of diagnostic value in dealing with cases of unusual lymphoma. Furthermore, nonrandom chromosome breakage exhibited three distinct patterns that reflected three levels of etiologically relevant genetic change. 相似文献
93.
Minasian LM; Szatrowski TP; Rosenblum M; Steffens T; Morrison ME; Chapman PB; Williams L; Nathan CF; Houghton AN 《Blood》1994,83(1):56-64
Hemorrhagic tumor necrosis is an inflammatory event that leads to selective destruction of malignant tissues, with both potentially toxic and beneficial consequences. A pilot clinical trial was undertaken combining tumor necrosis factor-alpha (TNF-alpha) with the monoclonal antibody R24 (MoAb R24) against GD3 ganglioside in patients with metastatic melanoma. Patients received MoAb R24 to recruit leukocytes to the tumor followed by low doses of recombinant TNF-alpha to activate leukocytes. Eight patients were treated and seven patients had mild toxicity. One patient with extensive metastatic melanoma developed tumor lysis syndrome within hours after treatment with almost complete necrosis of bulky tumors in multiple visceral sites. To our knowledge, this is the first documented case of hemorrhagic tumor necrosis in a patient with metastatic cancer in multiple visceral sites. 相似文献
94.
95.
Factor VIII coagulant protein (VIII:C) functions as a critical cofactor with factor IXa, calcium ions, and phospholipid during the activation of factor X. In the course of this reaction, the activity of VIII:C is first increased and then is destroyed by one or more serine proteases that are part of the coagulation sequence. In this study, we have investigated the influence of platelets on the inactivation of VIII:C by plasmin. Platelets were separated from plasma proteins in the presence of granule release inhibitors and were incubated with plasmin and isolated VIII:C or the complex of purified VIII:C/von Willebrand factor (vWF); VIII:C activity and antigen levels were assessed over time. In the presence of platelets, the isolated VIII:C showed an initial increase in VIII:C activity that was not present when platelets were absent, and the VIII:C/vWF showed an increase in VIII:C activity over that seen when platelets were absent. In addition, platelets stabilized VIII:C activity over a one-hour time course when compared with buffer. The VIII:C antigen did not increase and decreased slowly whether platelets were present or absent. Preincubating the platelets with ristocetin, collagen, or plasmin did not alter the results, and experiments using platelets from a patient with severe von Willebrand's disease also showed a pattern similar to that seen with normal platelets. Experiments using fixed platelets or phospholipid vesicles showed that they did not support the activation reaction or delay the inactivation reaction. These studies demonstrate that platelets modulate the activation and inactivation of VIII:C by plasmin, apparently by a mechanism that is independent of the platelet release reaction. 相似文献
96.
97.
Elene C. Pereira-Maia Ivina P. Souza Kelen J. R. C. Nunes Alexandre A. Castro Teodorico C. Ramalho Fernando Steffler Helio A. Duarte Ana Pacheli Poliana Chagas Luiz C. A. Oliveira 《RSC advances》2018,8(19):10310
A new class of polyoxoniobate complex has been synthesized and characterized as a novel anticancer agent for photodynamic therapy. The complex inhibits the growth of chronic myelogenous leukemia cells with an IC50 value of 30 μM, in the dark. However, upon exposure to light (365 nm) there is a fivefold increase in the cytotoxic activity. Light radiation activate the complex with the formation of radical species capable of interacting with DNA according to our experimental and theoretical data.A new class of polyoxoniobate complex has been synthesized and characterized as a novel anticancer agent for photodynamic therapy.In this work, we prepared a photosensitive peroxoniobium complex presenting a balance with an active radical phase when illuminated with radiation of 365 nm. A versatile niobium species of amorphous structure was obtained by the reaction of niobium ammonium oxalate with ammonium hydroxide up to pH 7. The material obtained, a niobium oxyhydroxide (NbO2(OH)) (white solid),1,2 can be modified with the generation of NbO2(OH)O2˙− peroxo groups (yellow solid).3 The yellow compound is formed by treatment with H2O2. The absorption radiation in the visible region due to the charge transfer transition between the peroxo group and the niobium is shown in Fig. 1.Open in a separate windowFig. 1UV-Vis profile of the catalysts.This complex with the radical as an intermediate is favored in the presence of visible and UV radiation. This property is of interest for photodynamic therapy of cancer (PDT), which involves the exposure of malignant cells containing a photosensitizer molecule to light irradiation, in the presence of oxygen species. The photoactivated drug produces reactive oxygen species that initiate a series of events, resulting in cell death. Selective light activation allows a preferential tumor destruction in comparison to healthy tissues.4 Several metal complexes exhibit photocytotoxicity under UV or visible light,5,6 but data about niobium compounds are very scarce in the literature.7The polyoxoniobate, generated from niobium oxyhydroxide described here can be very active in the treatment of diseased cells when illuminated with visible or UV radiation due to its light absorption capacity because of the peroxo groups formed. The peroxoniobium complex has some advantages, such as ease synthesis and in mild conditions, high solubility, low activity under light off, and resistance to inactivation by thiol reagents. Moreover, it is nontoxic8 and does not employ noble metals like most of the compounds proposed in the literature. Actually, niobium oxide was tested as a bone implant component and showed absence of inflammatory cells or degeneration of the osteoblasts without any sign of damage to the preexisting bone tissue, showing compatibility with the bone tissue.9–11The innovative part in the process of obtaining the polyoxoniobate complex presented in this work consists in the leaching of the complex when treating the niobium oxyhydroxide with H2O2. With the treatment, a yellow solid and a leached yellow liquid is obtained, which is the complex containing peroxoniobium in its structure, sensitive to the UV-Vis radiation generating radical species. This species generated with the leaching at neutral pH presents high negative charge and a kinetic volume of 223 nm. The XRD of the lyophilized polyoxoniobate indicated strong amorphous character. However, the polyoxoniobate is known to form well defined polyoxometalates such as Lindqvist ([Nb6O19]8−) and decaniobate ([Nb10O28]6−). Fig. 2 shows a comparison between the experimental and PBE/LANL2DZ/aug-cc-pVDZ DFT IR spectra. It is clear that the pattern of the decaniobate structure is closer to the experimental spectrum. One should keep in mind that DFT frequencies are normally 10% underestimated with respect to the experimental values. The broader absorption below 600 cm−1 can be attributed to the interaction between different decaniobate structures forming the amorphous solid. The calculated peaks at 710, 760 and 860 cm−1 are related to the experimental peaks of 800, 870 and 910 cm−1 indicating that decaniobate is the local arrangement of the polyoxoniobate complex.Open in a separate windowFig. 2Infrared spectra for experimental procedures, Lindqvist and decaniobate structures (simulated). The line shape chosen was Lorentzian and the half-width is about 20.The generation of reactive oxygen under radiation was confirmed by the reaction of the complex with an organic dye, which was monitored by UV-Vis spectroscopy (Fig. 3). The spectrum of the dye solution shows the characteristic peak of the methylene blue (MB) at 663 nm (black trace). It can be clearly seen that in the presence of the peroxoniobium complex and radiation (365 nm) the signal decreased indicating the reaction of the peroxoniobium complex with the dye (blue trace). In the absence of light, there is no decrease in the signal related to the dye, indicating the need of the radiation to activate the oxidation action of the peroxoniobium complex. The equilibrium in which the radical species forms it is not necessary to use a photosensitizer agent, such as porphyrins.4 A further investigation was carried out by 31P NMR (Fig. S1†) using guanosine as model molecule able to react with the peroxoniobium complex. The 31P NMR spectrum shown in Fig. S1-a† corresponds to 5-GMP and revealed that the phosphorus atom in the structure exhibits a chemical shift at δ 5.93. When 5-GMP and the polyoxoniobate are in contact, no significant changes are observed in the 31P spectrum, only a small displacement of the phosphorus signal to δ 5.90 (Fig. S1-b†). However, when the 5-GMP and polyoxoniobate mixture is submitted to radiation (Fig. S1-c†), an interaction between the compounds occurs, giving rise to a new species that presents a different chemical shift in the P spectrum (δ 5.27).Open in a separate windowFig. 3UV-Vis profile of the reaction of the Nb complex with the organic dye (10 mg L−1).The effect of the peroxoniobium on the growth of K562 cells was evaluated after 4 h of incubation. The compound inhibits K562 cell growth in a concentration-dependent manner, with an IC50 of 30.0 ± 1.5 μmol L−1. Ammonium niobate(v) oxalate was also tested and it has no effect on K562 cells up to 100 μM. The cytotoxic activity of polyoxoniobate increases by 5 times upon 5 min of UV-A light irradiation, with an IC50 value of 6.2 ± 0.4 μmol L−1 (Fig. 4). The higher activity, when exposed to light, associated to the low toxicity of niobium compounds place the peroxoniobium complex as a candidate for photodynamic therapy.Open in a separate windowFig. 4Photocytotoxic effect of the peroxoniobium complex. K562 cells were incubated for 4 h in the presence of different complex concentrations, in the dark (black bars) and after 5 min of UV-A light exposure (red bars). The values are the average of three independent experiments.There are few reports in the literature about the cytotoxic activity of niobium compounds. A peroxo niobium complex with ascorbic acid (K3[Nb(Asc)(O2)3]) is moderately active in HL60 human leukemia cells but not in K562 human myelogenous leukemia cells.12 A tetrameric Nb28-containing cluster inhibits the growth of the human breast cancer MCF-7 cells line with an IC50 value of 5.21, after 48 h of incubation.13Methylene blue (MB) is one of the main photosensitizing agents used in PDT due to its good tissue penetration and low cytotoxicity.14 It is active in several types of tumors upon irradiation with red laser light.15 This fact allied to the ability of the peroxoniobium compound to interact with MB (Fig. 3) prompted us to investigate its effect in the MB photocytotoxicity. We have first checked that exposure to UV-A light did not affect the cytotoxicity of MB in K562 cells (Compound IC50a IC50 irradiatedb MB 7.3 ± 0.4 7.0 ± 0.5 MB + NbO2(OH)–O2−c 6.3 ± 0.3 3.0 ± 0.1